1. Home
  2. Live Updates
  3. Clin cancer

Live Breaking News & Updates on Clin cancer

Stay informed with the latest breaking news from Clin cancer on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Clin cancer and stay connected to the pulse of your community

BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer

Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.

International-federation-of-gynecology , International-federation , Clin-cancer , Ovarian-cancer , Brca , Ovarian-cancer-treatment , Olaparib ,

Truqap plus Faslodex recommended for approval in the EU by CHMP for patients with advanced ER-positive breast cancer

AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or ...

United-kingdom , Canada , Japan , Cambridge , Cambridgeshire , Astrazeneca-truqap , Daiichi-sankyo , Cancer-research-technology , Committee-for-medicinal-products-human-use , World-health-organization , Investor-relations-team , National-comprehensive-cancer-network

APCCC 2024: How Do Non-DDR Genomic Alterations Influence Management of Patients with Advanced Prostate Cancer?

APCCC 2024: How Do Non-DDR Genomic Alterations Influence Management of Patients with Advanced Prostate Cancer?
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

Lugano , Ticino , Switzerland , Texas , United-states , Houston , Toronto , Ontario , Canada , Twitter , Department-of-genitourinary-medical-oncology

APCCC 2024: How to Identify Aggressive Variant Prostate Cancer?

APCCC 2024: How to Identify Aggressive Variant Prostate Cancer?
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

Dana-farber-cancer-institute , Massachusetts , United-states , Romanel , Switzerland-general- , Switzerland , Lugano , Ticino , Boston , Toronto , Ontario , Canada

AstraZeneca and Daiichi Sankyo's BLA for Datopotamab Deruxtecan Accepted by FDA for Advanced Breast Cancer Treatment

AstraZeneca and Daiichi Sankyo's BLA for Datopotamab Deruxtecan Accepted by FDA for Advanced Breast Cancer Treatment
news.europawire.eu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news.europawire.eu Daily Mail and Mail on Sunday newspapers.

United-kingdom , San-antonio , Texas , United-states , Sapporo , Hokkaido , Japan , Canada , Cambridge , Cambridgeshire , China , America

AstraZeneca : Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer - Form 6-K -April 02, 2024 at 07:58 am EDT

a9023i












FORM 6-K


SECURITIES AND EXCHANGE COMMISSION


...

United-kingdom , Cambridge , Cambridgeshire , Japan , United-states , Canada , Washington , San-antonio , Texas , Sapporo , Hokkaido , China

AstraZeneca : Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer -March 27, 2024 at 03:09 am EDT

First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations

Approval based on CAPItello-291 results which showed...

China , Japan , Canada , United-kingdom , Cambridge , Cambridgeshire , Japanese , Daiichi-sankyo , Astrazeneca-truqap , Nasdaq , National-comprehensive-cancer-network , European-union

Swissmedic Accepts Marketing Authorization Application for Piflufolastat (18F) for Prostate Cancer

Swissmedic has accepted for review a marketing authorization application seeking the approval of Piflufolastat (18F) for prostate cancer.

Switzerland , United-states , Swiss , Benoit-woessmer , Michel-wuillemin , Swiss-agency-for-therapeutic-products-swissmedic , Lantheus-holdings-inc , Swiss-agency , Therapeutic-products , European-medicines-agency , European-commission , Lantheus-holdings

Extending the Frontiers of Checkpoint Inhibition in Merkel Cell Carcinoma

In the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.

Boston , Massachusetts , United-states , Netherlands , Dana-farber-cancer-institute , Germany , American , Avelumab-bavencio , Jamesa-decaprio , Kangc-retifanlimab , American-society-of-clinical-oncology-annual-meeting , Harvard-medical-school

A Review of Anti-HER2 Targeted Agents in Non-Breast Solid Tumors

This review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.

South-korea , Japan , University-of-washington , Washington , United-states , Harwood , Seattle , American , Megan-alhadeff , Javlem-overexpression , Hanh-bui , Tiffany-tam